An observational study in Hepatocellular Carcinoma, sponsored by Eisai Co., Ltd.. Completed at 1 site in Japan. Per ClinicalTrials.gov, last updated 2018-11-05.
Sponsored by Eisai Co., Ltd. · Observational
This surveillance's objectives are:
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's enrollment of 300 is above the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →Eisai Co., Ltd. is the lead sponsor of 149 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with Hepatocellular carcinoma
Patients with Hepatocellular carcinoma
Exclusion criteria:
None
Device: E7040
E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
Also known as: DC Beads
Safety and Tolerability as measured by Adverse Events
Time frame: Up to 30 days
Efficacy of DC bead as assessed by embolic performance
Time frame: Up to 30 days
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eisai Co., Ltd.